Table 2. Univariate and multivariate Cox proportional hazard regression analysis of clinicopathologic features for biochemical recurrence.
| Factors | Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age (years) | 1.009 | 0.992–1.025 | 0.313 | 1.000 | 0.982–1.018 | 0.982 |
| BMI (kg/m2) | 0.972 | 0.936–1.011 | 0.154 | 0.965 | 0.925–1.006 | 0.090 |
| Preoperative PSA (ng/mL) | 1.022 | 1.009–1.036 | <0.001 | 1.013 | 1.008–1.216 | 0.018 |
| Prostate volume (mL) | 1.004 | 0.996–1.012 | 0.311 | 0.997 | 0.987–1.006 | 0.484 |
| Tumor volume (> 5mL) | 1.912 | 1.530–2.391 | <0.001 | 1.506 | 1.191–1.903 | 0.001 |
| Extracapsular extension | 0.943 | 0.517–1.720 | 0.847 | 1.378 | 0.709–2.679 | 0.345 |
| Seminal vesicle invasion | 2.348 | 1.890–2.917 | <0.001 | 1.588 | 1.245–2.026 | <0.001 |
| Positive surgical margin | 1.659 | 1.323–2.081 | <0.001 | 1.171 | 0.913–1.500 | 0.214 |
| Lymphovascular invasion | 2.038 | 1.635–2.541 | <0.001 | 1.357 | 1.064–1.730 | 0.014 |
| Perineural invasion | 1.392 | 1.002–1.684 | 0.023 | 1.278 | 1.039–1.896 | 0.230 |
| Pathologic Gleason score | ||||||
| ≤6 | Reference | Reference | ||||
| 7 (3+4) | 1.080 | 0.631–1.849 | 0.778 | 1.041 | 0.575–1.881 | 0.895 |
| 7 (4+3) | 2.087 | 1.229–3.546 | 0.006 | 1.731 | 1.001–3.119 | 0.048 |
| ≥8 | 4.247 | 2.528–7.137 | <0.001 | 3.127 | 1.744–5.606 | <0.001 |
| Adjuvant treatment | 2.301 | 1.216–3.482 | 0.002 | 1.562 | 0.913–2.896 | 0.231 |
HR, hazard ratio; CI, confidence interval; BMI, body mass index; PSA, prostate-specific antigen.